{"slideshow_credits": null, "snippet": "With a $21 billion deal, the pharmaceutical giant gets a blockbuster drug, but at a high cost: It must share profits with rival Johnson & Johnson.", "abstract": null, "section_name": "Business Day", "print_page": "", "document_type": "article", "byline": {"person": [{"firstname": "Robert", "role": "reported", "lastname": "CYRAN", "rank": 1, "organization": ""}], "original": "By ROBERT CYRAN"}, "web_url": "http://www.nytimes.com/2015/03/06/business/dealbook/why-abbvie-may-have-overpaid.html", "lead_paragraph": "With a $21 billion deal, the pharmaceutical giant gets a blockbuster drug, but at a high cost: It must share profits with rival Johnson & Johnson.", "headline": {"main": "Why AbbVie May Have Overpaid for Cancer Drug Maker", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "_id": "54f8bb4738f0d81f0d7a60c8", "word_count": "378", "multimedia": [], "pub_date": "2015-03-06T00:00:00Z", "source": "The New York Times", "news_desk": "Dealbook", "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "1"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "2"}, {"name": "subject", "value": "Biotechnology and Bioengineering", "is_major": "N", "rank": "3"}, {"name": "organizations", "value": "Pharmacyclics, Incorporated", "is_major": "N", "rank": "4"}, {"name": "organizations", "value": "AbbVie Inc", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "Johnson & Johnson", "is_major": "N", "rank": "6"}, {"name": "organizations", "value": "Shire PLC", "is_major": "N", "rank": "7"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}